Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.

Jazz Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $1.13 billion, up 6.7% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Jazz Pharmaceuticals’s revenue to grow 7.5% year on year, in line with the 7.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Jazz Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Ocular Therapeutix’s revenues decreased 22.4% year on year, missing analysts’ expectations by 11%, and Eli Lilly reported revenues up 42.6%, topping estimates by 7.4%. Ocular Therapeutix traded up 7.1% following the results while Eli Lilly was also up 1.7%.

Read our full analysis of Ocular Therapeutix’s results here and Eli Lilly’s results here.

The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Jazz Pharmaceuticals is up 5.2% during the same time and is heading into earnings with an average analyst price target of $219.40 (compared to the current share price of $172.05).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.